The vaccine developer has reached the conclusion after the second interim analysis of clinical trial data wherein the vaccine showed 91.4% efficacy on day 28 and 95% efficacy 42 days after the first dose is administered.
"Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose,": The Gamaleya National Center of Epidemiology and Microbiology.
Russia got worldwide attention when it claimed to have developed the world's first Coronavirus vaccine back in August. Sputnik V vaccine which is named after the Soviet Union spacecraft has been developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry.
Later on, November 11, the Russian government said that its vaccine Sputnik V is 92 percent effective at protecting people from Covid-19 according to the first interim analysis.
ALSO READ | Russian Covid-19 Vaccine To Be Cheaper Than Pfizer And Moderna, Says Sputnik V
In a recent development, it was confirmed that Russia developed vaccine’s price will be much lower than the vaccines of the US-based firms such as Pfizer and Moderna.
"Translating pharma lingo: the announced price of Pfizer of USD 19.50 and Moderna of USD 25-USD 37 per dose actually means their price of USD 39 and USD 50-USD 74 per person. Two doses are required per person for the Pfizer, Sputnik V, and Moderna vaccines. The price of Sputnik V will be much lower," the official account stated.
Meanwhile, a host of Coronavirus vaccines are showing promising results at a speed unlike ever before. Noting this development, the World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said "There is now real hope that vaccines, in combination with other tried and tested public health measures, will help to end the pandemic".
"The significance of this scientific achievement cannot be overstated. No vaccines in history have been developed as rapidly as these. The scientific community has set a new standard for vaccine development," Tedros added.
He further emphasised that the international community must set a new standard for access, as "the urgency with which vaccines have been developed must be matched by the same urgency to distribute them fairly."
WATCH | COVID-19 and Oxford vaccine in India, all about it | Namaste Bharat